Get access

New developments in the treatment of osteoporosis

Authors


  • Conflict of interest
    Erik Fink Eriksen is currently a member of Advisory Boards and receiving speaker fees from Eli Lilly, Novartis, Amgen and Novo Nordisk.
    Johan Halse is currently a member of Advisory Boards and receiving speaker fees from Amgen, MSD, Eli Lilly, Novartis, Novo, Nycomed and Pfizer.
    Mette Haase Moen is currently a member of Advisory Boards and receiving speaker fees from Amgen and Bayer Healthcare.

  • Please cite this article as: Eriksen EF, Halse J, Moen MH. New developments in the treatment of osteoporosis. Acta Obstet Gynecol Scand 2012;91:1273–1289.

Correspondence
Erik Fink Eriksen, Oslo University Hospital, Aker, Trondheimsveien 235, NO-0514, Oslo, Norway. E-mail: e.f.eriksen@medisin.uio.no

Abstract 

The last 25 years have seen the development of a plethora of new, effective agents for the treatment of osteoporosis. These agents reduce the risk of spine fractures by up to 70%, hip fractures by 40–50% and non-vertebral fractures by up to 50–80%. Amino-bisphosphonates, taken orally or intravenously, remain the dominant treatment modalities for osteoporosis. These so-called anti-resorptive or anti-catabolic agents stabilize the skeleton and reduce fracture risk in osteoporotic as well as osteopenic individuals. A monoclonal antibody against receptor activator of nuclear factor κB ligand, Denosumab, constitutes a new anti-resorptive agent recently approved worldwide. In younger postmenopausal women, low-dose estrogen or estrogen/progestin still has a place for short-term (up to 5 years) preservation of bone mass, especially in women with menopausal symptoms. Likewise, selective estrogen receptor modulators should be considered in younger postmenopausal women, especially those at increased risk of breast cancer. Anabolic (bone forming) regimens, of which parathyroid hormone is the only agent currently available, aid in the build up of new bone, increase bone mass and improve bone architecture. In cancellous bone, 30–60% increases of bone mass have been documented, but cortical bone thickness also increases. These improvements lead to profound reduction in fracture rates in both the axial and appendicular skeleton. Owing to cost and the need for parenteral administration, in most countries these agents are reserved for severe osteoporosis with multiple fractures.

Ancillary